These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11965228)

  • 1. Celecoxib: a specific COX-2 inhibitor with anticancer properties.
    Koki AT; Masferrer JL
    Cancer Control; 2002; 9(2 Suppl):28-35. PubMed ID: 11965228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib with chemotherapy in colorectal cancer.
    Blanke CD
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):17-21. PubMed ID: 12014863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K; Akay MT; Abbasoglu O; Ercan A
    Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
    Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ
    Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
    Elder DJ; Halton DE; Hague A; Paraskeva C
    Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2: a target for prevention and treatment of esophageal cancer.
    Altorki N
    J Surg Res; 2004 Mar; 117(1):114-20. PubMed ID: 15013721
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
    Masferrer JL; Leahy KM; Koki AT; Zweifel BS; Settle SL; Woerner BM; Edwards DA; Flickinger AG; Moore RJ; Seibert K
    Cancer Res; 2000 Mar; 60(5):1306-11. PubMed ID: 10728691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 inhibition and colorectal cancer.
    Koehne CH; Dubois RN
    Semin Oncol; 2004 Apr; 31(2 Suppl 7):12-21. PubMed ID: 15252926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
    Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cyclooxygenase inhibitors in cancer prevention.
    Anderson WF; Umar A; Viner JL; Hawk ET
    Curr Pharm Des; 2002; 8(12):1035-62. PubMed ID: 11945150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery.
    Reuben SS
    Spine (Phila Pa 1976); 2001 Jul; 26(13):1505-6. PubMed ID: 11458162
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
    Kawamori T; Rao CV; Seibert K; Reddy BS
    Cancer Res; 1998 Feb; 58(3):409-12. PubMed ID: 9458081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coming: a review of second-generation nonsteroidal anti-inflammatory drugs.
    Housholder GT; Chan JT
    J Gt Houst Dent Soc; 1997 Mar; 68(8):13-6. PubMed ID: 9594801
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
    Fischer SM; Lo HH; Gordon GB; Seibert K; Kelloff G; Lubet RA; Conti CJ
    Mol Carcinog; 1999 Aug; 25(4):231-40. PubMed ID: 10449029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.